A couple of weeks ago, we blogged about the strides being made to combat melanomas by releasing the brakes on the immune system. Last week, the FDA approved Bristol-Myers Squibb's Opdivo (nivolumab), an immunotherapy drug that has had dramatic results in lengthening the lives of patients with some late-stage melanomas.Read More
Up at 5AM: The 5AM Solutions Blog
Drug development is a long, expensive process with a very high failure rate. In a 2011 commentary in the journal Science Translational Medicine, NIH director Francis Collins described it like this:Read More
There is some good news in West Africa, as cases of Ebola are on the decline, even in Liberia, Sierra Leone, and Guinea, the continent's hardest hit areas.Read More
The California Institute for Regenerative Medicine (CIRM), has completely overhauled its process for funding projects to develop stem cell-based treatments and therapies. Beginning January 1, CIRM, which is California's voter-supported, grant- and loan-making agency funding stem cell research, will launch CIRM 2.0 which will shorten the time from application to funding from nearly two years to 120 days.Read More
One of the challenges in drug development is enrolling participants in clinical trials that meet very specific criteria. The reason for this is sound: make the trial too broad and researchers risk missing meaningful data about a potential therapy's efficacy.
However, there is a tension between mitigating that risk and the need to reach as many people with horribly debilitating -- and often life-threatening -- illnesses as possible with a life-altering miracle. Often multiple trials have to be conducted that test lots of different scenarios, and each one needs participants whose conditions, like the porridge and the bed in the fairy tale, are "just right."Read More
At ASHG 2014, I had the pleasure of listening to the talks of Ajay Royyuru from IBM’s Computational Biology Center, and David Glazer from Google, during the ‘Separating Signal from Noise’ symposium.Read More
"Don't want little Johnny or Betty to develop a crippling disease with the potential for lifelong paralysis? Then sign here and be a pioneer in improving global health!"Read More
With the death toll topping 3000 in West Africa, health agencies around the world are working to speed the development of treatments and vaccines against Ebola. According to the UN Security Council, the epidemic is "...a threat to international peace and security." Normally, taking medical treatments and vaccines from laboratories to patients is a lengthy process that can go on for years. Ebola is different.Read More
Twenty human subjects became participants in clinical trials for an Ebola vaccine. Almost 2300 people have died from the disease since January 2014 when an outbreak of the disease began and spread through western Africa. In an animal study, four crab eating macaques showed immunity to lethal doses of the virus when they were inoculated with a vaccine.Read More
This year, 2000 men in the U.S. will be diagnosed with breast cancer. Fewer than 500 of them will die from the disease. In general, men's chances of developing the disease are about 100 time less that of women's. Comparatively, about 200,000 women will receive a breast cancer diagnosis.